Physician profile
Dana Campetti
NPI 1124517750
$5,294.64
in general payments reported to CMS, 2019-2025
30 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $1,001 · 2023: $903 · 2024: $1,358 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $724.32 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.13 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $472.09 | 2022-2025 | |
| Janssen Biotech, INC. | $372.52 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $265.52 | 2023-2025 | Ibsrela |
| Pfizer INC. | $230.72 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $181.16 | 2022-2025 | Dupixent |
| Celgene Corporation | $181.02 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $153.56 | 2021-2023 | |
| Lilly USA, LLC | $142.06 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Medtronic, INC. | $124.75 | 2024 | Endoflip |
| Merck Sharp & Dohme LLC | $92.61 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $92.54 | 2021-2024 | Linzess |
| Celltrion USA INC. | $69.94 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $51.39 | 2022-2023 | Ocaliva |
| Qol Medical, LLC | $41.14 | 2022-2023 | Sucraid |
| Novo Nordisk INC | $35.00 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $29.48 | 2023-2024 | Idacio |
| Digestive Care, INC. | $26.76 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.66 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.13 | 2021 | |
| Amgen INC. | $18.58 | 2025 | Uplizna |
| Organon LLC | $14.92 | 2023 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $14.48 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $13.82 | 2024 | Bylvay |
| Redhill Biopharma INC. | $13.37 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.31 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Campetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.